HOME >> MEDICINE >> NEWS
ZYVOX(R) demonstrates high success rate for patients who develop MRSA surgical site infections

New York, Dec. 15, 2004 Surgical patients treated with Pfizer's novel antibiotic ZYVOX (linezolid; injection, tablets, and for oral suspension) had a significantly higher rate of microbiologic success (documented or presumed eradication) than those treated with intravenous (IV) vancomycin for surgical site infections (SSIs) caused by methicillin-resistant Staphylococcus aureus (MRSA), according to data published in the December issue of the American Journal of Surgery. In addition, the mean duration of IV treatment was significantly shorter (6 days) for patients who received ZYVOX than for those treated with vancomycin. Post-operative surgical site infections remain a major source of illness and number approximately 500,000 per year.

In the post-hoc analysis, patients in the MRSA subgroup treated with ZYVOX had microbiologic success rates of 87 percent compared to 48 percent for patients on vancomycin. Clinical cure rates for ZYVOX-treated patients were comparable to those treated with vancomycin for all SSIs, including those caused by MRSA. ZYVOX, available in interchangeable IV and oral formulations, is the only oral therapy approved by the U.S. Food and Drug Administration for MRSA infections.

Patients who develop SSIs are 60 percent more likely to spend time in an intensive care unit, five times more likely to be readmitted to the hospital and twice as likely to die. Hard-to-treat resistant bacteria such as MRSA are further complicating these infections. MRSA is extremely serious and can lead to prolonged hospitalization, increased morbidity, increased risk of mortality, and increased costs (driven by length of hospital stay). Data show that MRSA caused 30 percent of SSIs in 2000 compared to 24 percent in 1997.

"As the prevalence of surgical site infections caused by MRSA increases, identifying MRSA early and having alternatives to vancomycin becomes extremely important since any patient undergoing surgery is at risk," said
'"/>

Contact: Jeanne Traflet
Jeanne.Traflet@Pfizer.com
212-733-0127
Edelman Public Relations
15-Dec-2004


Page: 1 2 3 4 5

Related medicine news :

1. New study in Nature demonstrates protection against cell death during heart attack
2. New study demonstrates co-administration
3. New data demonstrates that Benicar(R) and Benicar HCT (TM) achieve JNC 7 blood pressure goals
4. New study demonstrates significant and sustained improvements in BPH symptoms with AVODART ™
5. New Canadian study demonstrates clear survival benefit of treatment in trials and at large centres
6. New study demonstrates key benefits of RISPERDAL(R) CONSTA(R) in young adults with schizophrenia
7. UF smart home demonstrates concept of automated elderly help and care
8. Study demonstrates improved survival in women with metastatic breast cancer
9. CHARM* Programme demonstrates clear benefits of Atacand in the treatment of heart failure
10. Residential addiction treatment demonstrates economic benefits
11. New P.E. study demonstrates vigorous exercise can lower adolescents body fat, blood pressure

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/10/2019)... ... July 10, 2019 , ... HMP, a leader in ... partner of the Oncology Clinical Pathways Congress, taking place October 11-13, 2019 in Boston. ... Clinical Pathways and focuses on the expansion of clinical pathways as a decision support ...
(Date:7/9/2019)... ... July 10, 2019 , ... First ... Client Services Manager and will lead the growing team of client services professionals ... Healthcare Compliance and look forward to further developing new healthcare client relationships in ...
(Date:7/9/2019)... ... , ... Women's Excellence is excited to offer laser vaginal rejuvenation. Laser vaginal rejuvenation gives women ... painful sex , vaginal dryness and burning , ... urgency , vaginal pH imbalances , recurrent vaginal infections , ...
(Date:7/9/2019)... ... July 09, 2019 , ... Leading healthcare digital ... of American Cancer Institutes – Clinical Research Innovation (AACI-CRI) annual meeting, held in ... and data analysis. As the leading provider of clinical research technology solutions, Forte ...
(Date:7/9/2019)... ... July 09, 2019 , ... A2LA is pleased to announce the accreditation of ... and solids. GEL Laboratories is based in Charleston, South Carolina, and is the first ... laboratory in the field of environmental testing to expand their scope to include hemp ...
Breaking Medicine News(10 mins):
(Date:7/12/2019)... ST. PETERSBURG, Fla. (PRWEB) , ... July 12, ... ... an interview of the MMJ International Holdings executives focusing on scientific research ... broadcast July 14, 2019 @ 1:30p.m. on CNBC. Check your local listings for ...
(Date:7/11/2019)... , ... July 11, 2019 , ... ... and Johnson and Nu Skin, and considered by a luminary of the cosmetic ... and organic oil consists of Sciadonic Acid DELTA-5, derived from exotic conifer seeds. ...
(Date:7/11/2019)... ... July 11, 2019 , ... Healthcare Information Management Leader ... of enterprise content management solutions, will exhibit at the 2019 Indiana Medical Group ... 19. , Conference attendees are encouraged to stop by booth #105 to ...
Breaking Medicine Technology:
Cached News: